Cytokine profiles at admission can be related to outcome in AIDS patients with cryptococcal meningitis

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Mora, Delio José ^a   Fortunato, Laila Rigolin ^a   Andrade Silva, Leonardo Eurípedes ^a   Ferreira Paim, Kennio ^a   Rocha, Ivonete Helena ^a   Vasconcelos, Rakel Rocha ^a   Silva Teixeira, David Nascimento ^a   Nascentes, Gabriel Antonio Nogueira ^a   Silva Vergara, Mario León ^a  

^a Federal University of Triângulo Mineiro   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; INTERLEUKIN DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD CULTURE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID ANALYSIS; COLONY FORMING UNIT; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; CRANIAL NERVE PARALYSIS; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIUM; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FUNGEMIA; FUNGUS CULTURE; HEADACHE; HOSPITAL ADMISSION; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION CONTROL; INTRACRANIAL HYPERTENSION; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PAPILLEDEMA; PROGNOSIS; SEIZURE; STIFF NECK; VIRUS LOAD; VOMITING; WEIGHT REDUCTION; AIDS RELATED COMPLEX; BLOOD; MIDDLE AGED;

FILOBASIDIELLA NEOFORMANS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BIOMARKERS; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKINS; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925729184     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120297     Document Type: Article

References (68)

1. Jarvis JN, Bicanic T, Loyse A, Namarika D, Jackson A, Nussbaum JC, et al. Determinants of Mortality in a Combined Cohort of 501 Patients with HIV-associated Cryptococcal Meningitis: Implications for Improving Outcomes. Clin Infect Dis. 2013; 58: 736-745. doi: 10.1093/cid/cit794 PMID: 24319084
2. Antinori S. New Insights into HIV/AIDS-Associated Cryptococcosis. ISRN AIDS. 2013; 25: 471363.
3. Anekthananon T, Manosuthi W, Chetchotisakd P, Kiertiburanakul S, Supparatpinyo K, Ratanasuwan W, et al. Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients. Int J STD AIDS. 2011; 22: 665-670. doi: 10.1258/ijsa.2011.010538 PMID: 22096053
4. Chuang YM, Ku SC, Liaw SJ, Wu SC, Ho YC, Yu CJ, et al. Disseminated Cryptococcus neoformans var. grubii infections in intensive care units. Epidemiol Infect. 2010; 138: 1036-1043. doi: 10.1017/S0950268809990926 PMID: 19796452
5. Pyrgos V, Seitz AE, Steiner CA, Prevots DR, Williamson PR. Epidemiology of cryptococcal meningitis in the US: 1997-2009. PLoS One. 2013; 8: e56269. doi: 10.1371/journal.pone.0056269 PMID: 23457543
6. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009; 23: 525-530. doi: 10.1097/QAD.0b013e328322ffac PMID: 19182676
7. Vidal JE, Penalva de Oliveira AC, Dauar RF, Boulware DR. Strategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin America. Braz J Infect Dis. 2013; 17: 353-362. doi: 10.1016/j.bjid.2012.10.020 PMID: 23665012
8. Lindenberg Ade S, Chang MR, Paniago AM, Lazéra Mdos S, Moncada PM, Bonfim GF, et al. Clinical and epidemiological features of 123 cases of cryptococcosis in Mato Grosso do Sul, Brazil. Rev Inst Med Trop Sao Paulo. 2008; 50: 75-78. PMID: 18488084
9. Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS. 2010; 5: 18-26. doi: 10.1097/COH.0b013e328333850f PMID: 20046144
10. Mora DJ, da Cunha Colombo ER, Ferreira-Paim K, Andrade-Silva LE, Nascentes GA, Silva-Vergara ML. Clinical, epidemiological and outcome features of patients with cryptococcosis in Uberaba, Minas Gerais, Brazil. Mycopathologia. 2012; 173: 321-327. doi: 10.1007/s11046-011-9504-9 PMID: 22130645
11. Brizendine KD, Baddley JW, Pappas PG. Predictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune status. PLoS One. 2013; 8: e60431. doi: 10.1371/journal.pone.0060431 PMID: 23555970
12. Dammert P, Bustamante B, Ticona E, Llanos-Cuentas A, Huaroto L, Chávez VM, et al. Treatment of cryptococcal meningitis in Peruvian AIDS patients using amphotericin B and fluconazole. J Infect. 2008; 57: 260-265. doi: 10.1016/j.jinf.2008.06.020 PMID: 18707764
13. Cachay ER, Caperna J, Sitapati AM, Jafari H, Kandel S, Mathews WC. Utility of clinical assessment, imaging, and cryptococcal antigen titer to predict AIDS-related complicated forms of cryptococcal meningitis. AIDS Res Ther. 2010; 7: 29. doi: 10.1186/1742-6405-7-29 PMID: 20682061
14. Siddiqui AA, Brouwer AE, Wuthiekanun V, Jaffar S, Shattock R, Irving D, et al. IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol. 2005; 174: 1746-1750. PMID: 15661940
15. Dromer F, Mathoulin-Pélissier S, Launay O, Lortholary O; French Cryptococcosis Study Group. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007; 4: e21. PMID: 17284154
16. Bicanic T, Muzoora C, Brouwer AE, Meintjes G, Longley N, Taseera K, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis. 2009; 49: 702-709. doi: 10.1086/604716 PMID: 19613840
17. Buchanan KL, Doyle HA. Requirement for CD4(+) T lymphocytes in host resistance against Cryptococcus neoformans in the central nervous system of immunized mice. Infect Immun. 2000; 68: 456-462. PMID: 10639404
18. Lindell DM, Moore TA, McDonald RA, Toews GB, Huffnagle GB. Generation of antifungal effector CD8+ T cells in the absence of CD4+ T cells during Cryptococcus neoformans infection. J Immunol. 2005; 174: 7920-7928. PMID: 15944298
19. Jarvis JN, Casazza JP, Stone HH, Meintjes G, Lawn SD, Levitz SM, et al. The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. J Infect Dis. 2013; 207: 1817-1828. doi: 10.1093/infdis/jit099 PMID: 23493728
20. Wormley FL Jr, Perfect JR, Steele C, Cox GM. Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect Immun. 2007; 75: 1453-1462. PMID: 17210668
21. Srikanth P, Castillo RC, Sridharan G, John TJ, Zachariah A, Mathai D, et al. Increase in plasma IL-10 levels and rapid loss of CD4+ T cells among HIV-infected individuals in south India. Int J STD AIDS. 2000; 11: 49-51. PMID: 10667901
22. Hernandez Y, Arora S, Erb-Downward JR, McDonald RA, Toews GB, Huffnagle GB. Distinct roles for IL-4 and IL-10 in regulating T2 immunity during allergic bronchopulmonary mycosis. J Immunol. 2005; 174: 1027-1036. PMID: 15634927
23. Zhang Y, Wang F, Tompkins KC, McNamara A, Jain AV, Moore BB, et al. Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99. Am J Pathol. 2009; 175: 2489-2500.
24. Ellerbroek PM, Walenkamp AM, Hoepelman AI, Coenjaerts FE. Effects of the capsular polysaccharides of Cryptococcus neoformans on phagocyte migration and inflammatory mediators. Curr Med Chem. 2004; 11: 253-266. PMID: 14754421
25. Vecchiarelli A. Fungal capsular polysaccharide and T-cell suppression: the hidden nature of poor immunogenicity. Crit Rev Immunol. 2007; 27: 547-557. PMID: 18197800
26. Boulware DR, Meya DB, Bergemann TL, Wiesner DL, Rhein J, Musubire A, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med. 2010; 7: e1000384. doi: 10.1371/journal.pmed.1000384 PMID: 21253011
27. Wijewardana I, Jarvis JN, Meintjes G, Harrison TS, Bicanic T. Large volume lumbar punctures in cryptococcal meningitis clear cryptococcal antigen as well as lowering pressure. J Infect. 2011; 63: 484-486. doi: 10.1016/j.jinf.2011.09.002 PMID: 21930156
28. Robertson EJ, Najjuka G, Rolfes MA, Akampurira A, Jain N, Anantharanjit J, et al. Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. J Infect Dis. 2014; 209: 74-82. doi: 10.1093/infdis/jit435 PMID: 23945372
29. Wozniak KL, Hardison SE, Kolls JK, Wormley FL. Role of IL-17A on resolution of pulmonary C. neoformans infection. PLoS One. 2011; 6: e17204. doi: 10.1371/journal.pone.0017204 PMID: 21359196
30. Wozniak KL, Kolls JK, Wormley FL Jr. Depletion of neutrophils in a protective model of pulmonary cryptococcosis results in increased IL-17A production by γδ T cells. BMC Immunol. 2012; 13: 65. doi: 10.1186/1471-2172-13-65 PMID: 23216912
31. Brouwer AE, Rajanuwong A, ChierakulW, Griffin GE, Larsen RA, White NJ, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004; 363: 1764-1767. PMID: 15172774
32. Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol. 1982; 15: 535-537. PMID: 7042750
33. Meyer W, Castañeda A, Jackson S, Huynh M, Castañeda E, IberoAmerican Cryptococcal Study Group. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis. 2003; 9: 189-195. PMID: 12603989
34. Kambugu A, Meya DB, Rhein J, O'Brien M, Janoff EN, Ronald AR, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008; 46: 1694-1701. doi: 10.1086/587667 PMID: 18433339
35. Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, Kanyemba C, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis. 2010; 50: 338-344. doi: 10.1086/649861 PMID: 20038244
36. Edwards VE, Sutherland JM, Tyrer JH. Cryptococcosis of the central nervous system. Epidemiological, clinical, and therapeutic features. J Neurol Neurosurg Psychiatry. 1970; 33: 415-425. PMID: 5535907
37. McClelland EE, Hobbs LM, Rivera J, Casadevall A, Potts WK, Smith JM, et al. The Role of Host Gender in the Pathogenesis of Cryptococcus neoformans Infections. PLoS One. 2013; 8: e63632. doi: 10.1371/journal.pone.0063632 PMID: 23741297
38. Loyse A, Wainwright H, Jarvis JN, Bicanic T, Rebe K, Meintjes G, et al. Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. AIDS. 2010; 24: 405-410. doi: 10.1097/QAD.0b013e328333c005 PMID: 19952714
39. Zhou Q, Gault RA, Kozel TR, Murphy WJ. Protection from direct cerebral cryptococcus infection by interferongamma- dependent activation of microglial cells. J Immunol. 2007; 178: 5753-5761. PMID: 17442959
40. Naranbhai V, Chang CC, Durgiah R, Omarjee S, Lim A, Moosa MY, et al. Compartmentalization of innate immune responses in the central nervous system during cryptococcal meningitis/HIV coinfection. AIDS. 2014; 28: 657-666. doi: 10.1097/QAD.0000000000000200 PMID: 24451162
41. Lortholary O, Sitbon K, Dromer F, French Cryptococcosis Study Group. Evidence for human immunodeficiency virus and Cryptococcus neoformans interactions in the pro-inflammatory and anti-inflammatory responses in blood during AIDS-associated cryptococcosis. Clin Microbiol Infect. 2005; 11: 296-300. PMID: 15760426
42. Netea MG, Brouwer AE, Hoogendoorn EH, Van der Meer JW, Koolen M, Verweij PE, et al. Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon- gamma therapy. Clin Infect Dis. 2004; 39: e83-87. PMID: 15494899
43. Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother. 2001; 12(3): 133-150. PMID: 12959322
44. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. Journal of Virology. 2009; 83: 3719-3733. doi: 10.1128/JVI.01844-08 PMID: 19176632
45. Osakwe CE, Bleotu C, Chifiriuc MC, Grancea C, Otelea D, Paraschiv S, et al. TH1/TH2 cytokine levels as an indicator for disease progression in human immunodeficiency virus type 1 infection and response to antiretroviral therapy. Roum Arch Microbiol Immunol. 2010; 69: 24-34. PMID: 21053781
46. Altfeld M, Addo MM, Kreuzer KA, Rockstroh JK, Dumoulin FL, Schliefer K, et al. T(H)1 to T(H)2 shift of cytokines in peripheral blood of HIV-infected patients is detectable by reverse transcriptase polymerase chain reaction but not by enzyme-linked immunosorbent assay under nonstimulated conditions. J Acquir Immune Defic Syndr. 2000; 23: 287-294. PMID: 10836750
47. Uicker WC, Doyle HA, McCracken JP, Langlois M, Buchanan KL. Cytokine and chemokine expression in the central nervous system associated with protective cell-mediated immunity against Cryptococcus neoformans. Med Mycol. 2005; 43: 27-38. PMID: 15712606
48. Kawakami K. Regulation by innate immune T lymphocytes in the host defense against pulmonary infection with Cryptococcus neoformans. Jpn J Infect Dis. 2004; 57: 137-145. PMID: 15329444
49. Voelz K, Lammas DA, May RC. Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans. Infect Immun. 2009; 77: 3450-3457. doi: 10.1128/IAI.00297-09 PMID: 19487474
50. Pietrella D, Kozel TR, Monari C, Bistoni F, Vecchiarelli A. Interleukin-12 counterbalances the deleterious effect of human immunodeficiency virus type 1 envelope glycoprotein gp120 on the immune response to Cryptococcus neoformans. J Infect Dis. 2001; 183: 51-58. PMID: 11087201
51. Singh N, Husain S, Limaye AP, Pursell K, Klintmalm GB, Pruett TL, et al. Systemic and cerebrospinal fluid T-helper cytokine responses in organ transplant recipients with Cryptococcus neoformans infection. Transpl Immunol. 2006; 16: 69-72. PMID: 16860707
52. Lipovsky MM, Gekker G, Hu S, Ehrlich LC, Hoepelman AI, Peterson PK. Cryptococcal glucuronoxylomannan induces interleukin (IL)-8 production by human microglia but inhibits neutrophil migration toward IL-8. J Infect Dis. 1998; 177: 260-263. PMID: 9419203
53. Lortholary O, Dromer F, Mathoulin-Pélissier S, Fitting C, Improvisi L, Cavaillon JM, et al. Immune mediators in cerebrospinal fluid during cryptococcosis are influenced by meningeal involvement and human immunodeficiency virus serostatus. J Infect Dis. 2001; 183: 294-302. PMID: 11110651
54. Chaka W, Heyderman R, Gangaidzo I, Robertson V, Mason P, Verhoef J, et al. Cytokine profiles in cerebrospinal fluid of human immunodeficiency virus-infected patients with cryptococcal meningitis: no leukocytosis despite high interleukin-8 levels. J Infect Dis. 1997; 176: 1633-1636. PMID: 9395381
55. Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker LG, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis. 2007; 45: 76-80. PMID: 17554704
56. Maxeiner HG, Marion Schneider E, Kurfiss ST, Brettschneider J, Tumani H, Bechter K. Cerebrospinal fluid and serum cytokine profiling to detect immune control of infectious and inflammatory neurological and psychiatric diseases. Cytokine. 2014; 69: 62-67. doi: 10.1016/j.cyto.2014.05.008 PMID: 25022963
57. Wirleitner B, Neurauter G, Schröcksnadel K, Frick B, Fuchs D. Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem. 2003; 10: 1581-1591. PMID: 12871129
58. Mao LY, Ding J, Peng WF, Ma Y, Zhang YH, Fan W, et al. Interictal interleukin-17A levels are elevated and correlate with seizure severity of epilepsy patients. Epilepsia. 2013; 54: e142-145. doi: 10.1111/epi.12337 PMID: 23944193
59. Rudner X, Happel KI, Young EA, Shellito JE. Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect Immun. 2007; 75: 3055-3061. PMID: 17403873
60. Kozakiewicz L, Chen Y, Xu J, Wang Y, Dunussi-Joannopoulos K, Ou Q, et al. B cells regulate neutrophilia during Mycobacterium tuberculosis infection and BCG vaccination by modulating the interleukin- 17 response. PLoS Pathog. 2013; 9: e1003472. doi: 10.1371/journal.ppat.1003472 PMID: 23853593
61. Stenzel W, Müller U, Köhler G, Heppner FL, Blessing M, McKenzie AN, et al. IL-4/IL-13-dependent alternative activation of macrophages but not microglial cells is associated with uncontrolled cerebral cryptococcosis. Am J Pathol. 2009; 174: 486-496. doi: 10.2353/ajpath.2009.080598 PMID: 19147811
62. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008; 226: 205-218. doi: 10.1111/j.1600-065X.2008.00706.x PMID: 19161426
63. Pappas PG, Bustamante B, Ticona E, Hamill RJ, Johnson PC, Reboli A, et al. Recombinant interferongamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis. 2004; 189: 2185-2191. PMID: 15181565
64. Jarvis JN, Meintjes G, Rebe K, Williams GN, Bicanic T, Williams A, et al. Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS. 2012; 26: 1105-1113. doi: 10.1097/QAD.0b013e3283536a93 PMID: 22421244
65. Clemons KV, Lutz JE, Stevens DA. Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice. Antimicrob Agents Chemother. 2001; 45: 686-689. PMID: 11181343
66. Lutz JE, Clemons KV, Stevens DA. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J Antimicrob Chemother; 2000; 46: 437-442. PMID: 10980171
67. Kawakami K, Tohyama M, Xie Q, Saito A. IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin Exp Immunol. 1996; 104: 208-214. PMID: 8625510
68. Clemons KV, Brummer E, Stevens DA. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother. 1994; 38: 460-464. PMID: 7911289